FDA Issues Draft Guidance Letting Gene-Editing Developers Reuse Platform Data Across Products to Speed Submissions
The FDA's June 2 draft guidance lets genome-editing sponsors leverage prior CMC, nonclinical, and clinical knowledge across products, with a 90-day comment window.